Cost-effectiveness is highly price-sensitive; lower U.S. prices, particularly approaching European levels, shift semaglutide toward favorable value rather than a binary go/no-go determination. Patient ...

But recent decades have seen a renewed interest in involuntary treatment specifically for substance use disorder. As of early 2026, 37 states and the District of Columbia have laws allowing ...

As healthcare costs continue to rise, businesses face increasing pressure to balance comprehensive benefits with financial sustainability. One of the most significant challenges is the escalating cost ...

This activity constitutes Phase 1 of a possible two-part effort directed towards guiding future benefit-cost studies, ensuring greater consistency and comparability across studies, and enhancing the ...

Medicine stands at a remarkable crossroads. The explosive growth in specialty drug development marks a new golden age of therapeutic innovation. In 1990 there were just 10 specialty drugs on the ...